| Species |
Cynomolgus |
| Protein Construction |
CDH3/Cadherin 3 (Asp108-Gly654)
Accession # XP_005592414.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
AntiCDH3 Antibody captured on CM5 Chip via Protein A can bind CDH3/Cadherin 3, His, Cynomolgus in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
61.11 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Placental-Cadherin (CDH3), a cell adhesion molecule, is associated with the function of cells to bind with other cells and the extracellular matrix (ECM). CDH3 is highly expressed in many malignancies, and has been proved it could be a serum marker to monitor colorectal cancer. Inhibited CDH3 expression could upregulate E-cadherin, downregulated N-cadherin, which may control invasion and migration. |
| Synonyms |
Cadherin-3; Placental cadherin; P-cadherin; CDH3; CDHP; HJMD; PCAD; PCADP-cadherin; CAD3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
